Keenan O'Dea

6PUBLICATIONS
36CO-AUTHORS
Major global burdens of diseaseInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 13, 2026
Genomic heterogeneity of NAD(P)H dehydrogenase predisposes Cryptosporidium to clofazimine resistance.

|Nov 24, 2025
Widespread genomic heterogeneity at the type II NAD(P)H dehydrogenase locus predisposes Cryptosporidium to clofazimine resistance.

Gracyn Y Buenconsejo, Sebastian Shaw, Rui Xiao

|Jun 06, 2025
An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses.

Emily A Aunins, Anthony T Phan, Mohamad-Gabriel Alameh

|Jun 03, 2024
Intestinal cDC1s provide cues required for CD4+ T cell-mediated resistance to Cryptosporidium.

Ian S Cohn, Bethan A Wallbank, Breanne E Haskins

|May 18, 2022
A genetic screen identifies a protective type III interferon response to Cryptosporidium that requires TLR3 dependent recognition.

Alexis R Gibson, Adam Sateriale, Jennifer E Dumaine

|Apr 19, 2022
PD-L1-PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection.

Joseph A Perry, Lindsey Shallberg, Joseph T Clark

Pageof 1

Frequent Collaborators

4 joint publications

Boris Striepen

3 joint publications

Jodi A Gullicksrud

3 joint publications

Christopher A Hunter

3 joint publications

Sebastian Shaw